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Background. The study aimed to describe the kinetics of various cytokines from day 1 to day 14 of the onset of fever in neutropenic
children and to evaluate their performances as discriminators of sepsis in the first 24 hours of fever, the possible influence of
filgrastim, and the functioning of the IL-23/IL-17 axis. Methods. IL-1β, TNF-α, IL-10, IL-12/23p40, IL-21, IL-6, IL-8, IL-17,
G-CSF, and GM-CSF were measured in plasma on days 1, 2, 3, 5, and 14 from the onset of fever in 35 patients. Results. Thirteen
patients (37.1%) developed sepsis. In mixed models, IL-6, IL-8, IL-10, and G-CSF showed higher estimated means in septic
patients (P < 0 005), and IL-12/23p40 and IL-17 in nonseptic patients (P < 0 05). On day 1, IL-6, IL-8, and IL-10 appeared
upregulated in patients who received filgrastim. Only IL-6, IL-8, IL-10, and procalcitonin were useful as discriminators of sepsis.
Associating the markers with each other or to a risk assessment model improved performance. Conclusions. Cytokines kinetics
showed proinflammatory and anti-inflammatory responses similar to what is described in nonneutropenic patients. IL-8, IL-6,
IL-10, and procalcitonin are useful as early biomarkers of sepsis. Filgrastim upregulates expression of these markers, and we
observed deficiency in the IL-23-IL-17 axis accompanying sepsis.
1. Introduction
The complex interactions that initiate the inflammatory
response in sepsis can be triggered by molecules expressed
by pathogens (PAMPs or pathogen-associated molecular
patterns) or derived from the injured tissues themselves
(DAMPs or damage-associated molecular patterns). Inflam-
matory processes that originate from bacterial infections
can be similar, in terms of fever and expression of mediators,
to the ones arising from traumatic tissue injury and tumors
[1, 2]. Diagnosing bacterial infections in children with cancer
can pose difficulties, due to inflammation already present by
intermittent exposure to signaling DAMPs released from
normal or malignant cells destroyed by cytotoxic treatment.
These children often present signs of systemic inflammatory
response syndrome (SIRS), such as fever and tachycardia in
the absence of infection (sterile inflammation). However,
the rapid diagnosis of infections in these patients is critical
because the delay in the administration of appropriate
antibiotics is associated with high mortality. Furthermore,
chemotherapy is postponed in the presence of infection.
Thus, differentiating sterile inflammation from infection is
also important to avoid interruptions in treatment [3–5].
Information on proinflammatory and anti-inflammatory
immune responses has increased in the recent years, demon-
strating sepsis as a highly dynamic biological process, with
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immunosuppression signals coexisting with the inflamma-
tion from the initial stages [6]. One of the immunosuppres-
sive mechanisms is deficient production of inflammatory
cytokines, such as IL-1β, IL-12, TNF-α, and IL-6, without
reduction or with increase in production of anti-
inflammatory cytokines such as IL-10, by macrophages, and
by monocytes undergoing reprogramming [7, 8]. These
mechanisms augment the immunosuppression already pres-
ent in the patient with cancer. Inflammatory signs and symp-
toms are usually described as attenuated in infections of
febrile neutropenic patients [9], assuming that inflammatory
response is also attenuated, but which is in fact understudied.
Although mediators such as IL-8 and IL-6 have been evalu-
ated in febrile neutropenic children as risk markers for severe
infections, the kinetics of cytokines during the time of fever
or occurrence of sepsis has been rarely studied [10]. We
found no data, for example, about the behavior of the
IL-23/IL-17 axis, associated with protective immunity at muco-
sal surfaces [11], a decisive factor in bacterial translocation in
patients undergoing chemotherapy. In addition, there are no
data on potential pro- or anti-inflammatory effects of filgras-
tim, an analogue of cytokine granulocyte colony-stimulating
factor (G-CSF) widely used in the treatment of neutropenia.
The main objectives of this study were to investigate the
dynamics of the inflammatory and anti-inflammatory
responses in febrile neutropenic children, throughout the
progression of intercurrent sepsis and recovery of leukocytes,
by means of the measurement of circulating cytokines
(IL-1β, TNF-α, IL-10, IL-12/23p40, IL-21, IL-6, IL-8, IL-17,
G-CSF, and GM-CSF) in plasma. Also, we aimed to evaluate
the performance of these cytokines as sepsis discriminators
compared with procalcitonin (PCT) and a clinical/laboratory
model for risk assessment on the first day of fever. Secondary
objectives were to assess the possible influence of filgrastim
on the expression of these markers and the proper function-
ing of IL-17/IL-23 axis in these patients.
2. Methods
The protocol was approved by the local Ethics Committee.
After informed consent was obtained from parents, patients
aged up to 18 years (incomplete) were sequentially included,
according to the following criteria: presence of an oncologic
disease and low- or high-risk for febrile neutropenia (accord-
ing to a high-risk assessment model based on clinical data
and CRP; Table 1). Patients were followed for 60 days. Sepsis
was defined according to the 2005 consensus [12]. Blood
samples (2mL) were collected from patients on the first day
of fever in children with neutropenia and then on days 2, 3,
5, and 14. After centrifugation and separation of plasma,
samples were frozen initially at −20°C and posteriorly at
−80°C. IL-1β, TNF-α, IL-10, IL-12/23p40, IL-21, IL-6, IL-8,
IL-17, G-CSF, and GM-CSF were measured using the Cyto-
metric Bead Array (CBA) Flex Set from Becton & Dickinson
(BD Biosciences, San Jose, CA, USA). PCT was measured by
ELISA (Human Procalcitonin ELISA, Biovendor, Brno,
Czech Republic). Additional blood samples (2mL) were
collected in EDTA tubes for blood cell analyses, which were
performed in automated counter (Cell-Dyn Ruby, Abbott,
Illinois, USA), with microscopic examination of blood smear
by the hematologist when necessary.
Data were analyzed with SPSS 20.0 software (IBM Corp.,
Armonk, NY, USA) and Minitab 17 (Minitab Inc., State
College, PA, USA). The variables were described as medians
and interquartile ranges. The value of significance was
P < 0 05. Differences between groups were evaluated using
the Mann–Whitney U test. Correlations were assessed by
the Spearman test and linear regression. Bootstrap was used
to determine the confidence intervals and the standard error
with resampling of at least 1000 tables. ROC curves were used
to assess usefulness of markers as discriminators of sepsis.
Optimal cutoff points were determined by the Youden J
index (J= {maximum sensitivity + specificity− 1}) [13]. Like-
lihood ratios were calculated to assess the possible influence
of the tests in clinical decisions [14].
3. Results
We included 35 patients, whose epidemiological character-
istics are shown in Table 2. Circulating cytokine, PCT, and
CRP levels at admission and during follow-up are shown
in Table 3.
Table 1: Definition of febrile neutropenia and risk assessment
model for serious infections.
Definition of low-risk febrile neutropenia
(i) Neutrophil count (<500 cells/μL)
(ii) Fever (one axillary temperature >38°C, or 3 measures >37.5
and <38°C, with a 4-hour interval between measurements, in
24 hours)
(iii) Solid tumors without comorbidities (see below)
(iv) Acute lymphoblastic leukemia (ALL) in remission without
comorbidities
(v) Lymphomas in remission without comorbidities
(vi) C-reactive protein (CRP) (<90mg/L)
(vii) Treatment: outpatient (daily monitoring until the end of
antibiotic therapy)
Definition of high-risk febrile neutropenia
(i) Neutrophil count (<500 cells/μL)
(ii) Fever (one axillary temperature >38°C, or 3 measures >37.5
and <38°C, with a 4-hour interval between measurements, in
24 hours)
(iii) Acute myeloid leukemia (AML) in activity or remission
(iv) Solid tumors with comorbidities (see below) or treated with
high-dose chemotherapy
(v) Acute lymphoblastic leukemia in activity or comorbidities
(vi) Lymphomas in activity or comorbidities
(vii) CRP >90mg/L
(viii) Treatment: in hospital
Comorbidities
(i) Meningitis, pneumonia, diarrhea or vomiting, mucositis
grade 3 or 4, hypotension, signs of sepsis or bacteremia,
metabolic changes, disease activity with medullary invasion,
age <3 years, suspected catheter-related infections, severe
abdominal pain or abdominal distension, radiologic findings
suggestive of typhlitis, perianal abscess
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Thirteen patients (37.1%) developed sepsis within 72
hours after diagnosis of febrile neutropenia. Of these, six
showed clinical signs of severe sepsis and four had septic
shock. Nine of the thirteen patients who developed sepsis
were initially categorized as high risk. Bacteria were found
in ten septic patients: in eight patients via blood culture (four
catheter-drawn and four venipuncture) and in two patients
via urine cultures. Blood cultures were positive for three
coagulase-negative staphylococci (two Staphylococcus epider-
midis, one Staphylococcus caprae), one Enterococcus raffino-
sus, two E. coli, and one Enterobacter sp. In one case, the
same bacterium (Pseudomonas oryzihabitans) was isolated
both in peripheral and catheter blood cultures. Two urine
cultures were positive for Klebsiella pneumoniae. In three
patients with signs of shock, no bacteria were recovered.
There were no deaths within 60 days after enrollment. Six
patients (17.1%) were admitted to the intensive care unit
(ICU). The kinetics of cytokines in septic and nonseptic
patients is shown in Figure 1.
3.1. Factor Analysis.Cytokines were included in a factor anal-
ysis model comprising the five moments of measurement.
The cumulative total variance explained by the model was
94.1%, with a Kaiser–Meyer–Olkin measure of sampling ade-
quacy of 0.85 and Bartlett’s sphericity test with P < 0 0001.
The model reduced the 10 variables to three factors, whose
loadings are shown in Table 4. G-CSF presented communal-
ity <0.4 and was removed.
The scores computed for factors 1, 2, and 3 were analyzed
by mixed models with repeated measurements and sepsis as
fixed effects. Factor 2, representing IL-6, IL-8, and IL-10
loadings, showed different estimated means between sepsis
and nonsepsis (−0.34 and 0.33; P = 0 000) and negatively
correlated (Spearman) with number of neutrophils (coeffi-
cient: −0.56; P = 0 000), lymphocytes (−0.36; P = 0 001),
and monocytes (−0.43; P = 0 000). Factor 1, representing
IL-1β, IL-17, IL-12/23p40, IL-17, IL-21, and TNF-α loadings,
showed a negative correlation (coefficient: −0.39; P = 0 013)
with CRP and positive with the number of neutrophils (coef-
ficient: 0.36; P = 0 001) and monocytes (coefficient: 0.23;
P = 0 035). Factor 3, comprising GM-CSF loading, showed
a negative correlation with the total number of monocytes
(coefficient: −0.23; P = 0 037). Factors 1 and 3 showed no
differences in estimated means for sepsis.
3.2. Mixed Models for Individual Markers. IL-6 showed
significant temporal variation (negative slope) between day
1 and day 3 (estimated mean difference: −209 pg/mL;
P = 0 000), between day 1 and day 5 (mean difference:
−173.7; P = 0, 02), and between day 1 and day 14 (−242.5;
P = 0 000). In the evaluation of sepsis as a fixed effect, the
estimated means were 181.1 pg/mL for septic patients and
24.8 for the others (P = 0 000).
IL-8 showed different estimated means for patients who
developed sepsis (265.9 pg/mL) and patients who did not
(40.9; P = 0 0000). It also showed significant temporal varia-
tion with negative slope between day 1 and day 3 (estimated
mean difference: −364 pg/mL; P = 0 002), between day 1 and
day 5 (−363.5 pg/mL; P = 0 003), and between day 1 and day
14 (−434.7; P = 0 000).
For IL-10, the estimated means were also different
between patients with sepsis and nonseptic patients (8.5 pg/
mL and 1.9; P = 0 004). There was significant temporal vari-
ation, with negative slope between day 1 and day 2 (estimated
mean difference: −11.5; P = 0 038), between day 1 and day 3
(−14; P = 0 011), between day 1 and day 5 (difference: −14.9;
P = 0 007), and between day 1 and day 14 (−15.6; P = 0 005).
Figure 2 shows the fitting lines for IL-6, IL-8, and IL-10, for
septic and nonseptic patients.
IL-12/23p40 had higher estimated means for the nonoc-
currence of sepsis (263.3 pg/mL versus 93.5 for sepsis;
P = 0 044). There was no significant temporal variation.
IL-17 also showed no significant temporal variation. For
patients who developed sepsis, the estimated means were
2.22 pg/mL, and for the others, 26.5 pg/mL (P = 0 04). The
correlation between IL-17 and IL-12/23p40 was linear with
R2 = 0.88 (P = 0 000). Figure 3 shows the fitting lines of
IL-12/23p40 and IL-17 along the measurements and their
linear regression.
There was no significant temporal variation of IL-1β. For
patients with sepsis, the estimated means were 7.7, and for
nonseptic patients, 0.41 pg/mL (P = 0 11). IL-21 showed
expression in only one nonseptic patient on day 1, with
erratic expression in a few other patients along the days,
and was not analyzed in mixed models.
GM-CSF showed estimated means of 1.3 and 1.8 pg/mL
for patients with sepsis or not (P = 0 15). There was no
significant temporal variation.
TNF-α had estimated means of 1.44 pg/mL for patients
with sepsis, and 4.6 (P = 0 16) for nonseptic patients, also
with no significant temporal variation.
Leukocytes (total counts) showed significant temporal
variation (positive slope), with a mean difference of +1369
cells/μL between day 1 and day 5 (P = 0 003) and +3059
Table 2: General data (N, %). IQR: interquartile range.
N 35
Age (years, median, IQR) 5.84 (3.7–10.3)
Male 10 (28.6%)
Received antibiotics 35 (100%)
Diagnoses
Acute lymphocytic leukemia 6 (17.1%)
Acute myelogenous leukemia 3 (8.6%)
Non-Hodgkin’s lymphoma 6 (17.1%)
Wilms’ tumor 4 (11.4%)
Primitive neuroectodermal tumor (PNET) 2 (5.7%)
Retinoblastoma 2 (5.7%)
Ewing’s sarcoma 2 (5.7%)
Chronic myeloid leukemia 1 (2.9%)
Other solid tumors 9 (25.7%)
Received filgrastim 19 (54.2%)
Days receiving filgrastim before day 1
of the study (mean, range)
4.5 (1–7)
Low risk 11 (31.5%)
High risk (hospitalized) 24 (68.5%)
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cells/μL between day 1 and day 14. For septic patients, the
mean estimated leukocyte counts were 1608 cells/μL versus
2067 cells/μL for nonseptic patients (P = 0 3). For neutro-
phils, the estimated means were 967 and 745 cells/μL for
septic patients or nonseptic patients (P = 0 46). There was
an increase along the days (mean difference: +1850 cells/μL
to day 14; P = 0 036). Lymphocytes also showed an increase
up to day 14 (+745 cells/μL; P = 0 02). For septic patients
or nonseptic patients, the estimated means were 483.1 and
292.2 cells/μL (P = 0 08). Figure 4 shows the temporal
variation in the number of leukocytes.
Monocytes showed significant temporal variation
between day 1 and day 3 (positive slope, mean difference:
235 cells/μL; P = 0 03), between day 1 and day 5 (+371.8
cells/μL; P = 0 03), and between day 1 and day 14 (+592
cells/μL; P = 0 001). For septic patients or nonseptic patients,
the estimated means were 347 and 391 cells/μL (P = 0 63).
When the occurrence of positive blood cultures was added
to the model, the estimated means were 107.8 and 257.8
cells/μL for septic or nonseptic patients (P = 0 017).
Platelets decreased between the days 1 and 2 (mean
difference: −46,827 platelets/μL; P = 0 027), increasing until
day 14 (+48,361 platelets/μL; P = 0 028). There were no
significant differences related to the occurrence of sepsis.
The CRP showed estimated means of 106.1mg/L for
septic and 52.9 for nonseptic patients (P = 0 14), with
significant temporal variation from days 1 to 5 (negative
slope, mean difference: −141.5).
Table 3: Values of biomarkers in the 5 days of measurements in median and interquartile ranges (25–75 percentiles).
Day Median IQR p25–75 Median IQR p25–75
IL-8 (pg/mL) IL-12/23p40 (pg/mL)
1 89.9 32.8–243.2 63.7 30.6–203.8
2 46.2 19.2–133.4 67.3 10.4–110.9
3 24.9 13.5–58.6 77.2 34.5–162.8
5 20.5 13.5–50.7 66.2 26.3–128.5
14 16.3 8.9–24.6 132.6 51–191.9
IL-6 (pg/mL) IL-10 (pg/mL)
1 57.3 31–198.2 2.2 0.6–10.2
2 21.6 10.1–49.9 2.6 0.1–5.4
3 12.7 5.9–36 1.8 0.8–3.3
5 11.9 4.7–35.6 1.1 0–1.7
14 6.3 3.8–7.7 0.4 0–1.7
IL-21 (pg/mL) TNF-α (pg/mL)
1 0 0-0 0 0–2.65
2 0 0-0 0 0–1.5
3 0 0-0 0.6 0–2.5
5 0 0-0 0.3 0–1.7
14 0 0-0 1.7 0–2.8
IL-1β (pg/mL) G-CSF (pg/mL)
1 0 0-0 2182.7 282.7–5739.5
2 0 0 2350.2 356–4793.9
3 0 0 947.9 139.9–4125
5 0 0-0.5 177 31–2232.4
14 0 0 28.1 15.5–50
IL-17 (pg/mL) GM-CSF (pg/mL)
1 0 0–2.6 0.1 0–2.8
2 0.5 0–3.7 0.9 0–3.4
3 1.1 0–4.9 0.6 0–2.4
5 1.6 0–2.8 0.6 0–1.9
14 2.8 0.5–6.4 1.6 0.4–2
C-reactive protein (mg/L) Procalcitonin (pg/mL)
1 56 28.9–98 149.1 0–909.6
2 78.5 61.8–95.3
3 87.2 54.2–130.6
5 47.7 16.2–87.5
14 7.7 5.7–7.2
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3.3. Filgrastim and Cytokine Levels. Among the patients
included, 19 were receiving filgrastim at the time of inclusion
in accordance with chemotherapy protocols. Eight (42%) of
these patients developed sepsis. On the first day of fever,
IL-6, IL-8, IL-10, and G-CSF showed differences in the distri-
bution or in the medians of patients who received filgrastim
and those who did not. For IL-6, IL-8, and G-CSF, the differ-
ences on the Mann–Whitney U test remained significant
after removal of septic patients: for IL-8, P = 0 042, 99% CI
0.037–0.047; IL-6, P = 0 006, 99% CI 000.3–0.006; and
G-CSF, P = 0 000. Despite the higher median of PCT in
the patients who received filgrastim, the difference was not
significant (Table 5).
In the mixed model, G-CSF presented different estimated
means between septic and nonseptic patients (2685.76 and
1509.6; P = 0 009). The temporal variation was significant
(negative slope), with a mean difference of −1608 between
day 1 and day 5 and −3191 between day 1 and day 14.
3.4. Analysis of the Biomarkers as Sepsis Discriminators.
Septic and nonseptic patients showed significant differ-
ences at day 1 by the Spearman test for IL-8, IL-6,
IL-10, and PCT. These markers were tested with ROC
curves as discriminators of sepsis, and their performances
are shown in Table 6. The performances of the cutoff
values of the biomarkers, their combinations, and the
comparison with the high-risk assessment model are
shown in Table 7.
Optimal cutoff points were determined by the Youden J
index, ranging from 0 (zero—no accuracy) and 1 (perfect
test) [13]. For LR+, values >10 have a great impact on diag-
nosis; between 5 and 10, moderate impact; and between 2
and 5, low impact. For LR−, values <0.1 have a great impact.
The impact is moderate for values between 0.1 and 0.2 and
low for values between 0.2 and 0.5. For both, values equal
to 1 show no impact [14].
The use of filgrastim caused minor changes in the areas
under the ROC curves of IL-8 (0.88; P = 0 04) and IL-6
(0.78; P = 0 037) for sepsis discrimination. For patients
who did not receive filgrastim, the AUC was 0.83 for IL-8
(P = 0 034) and 0.9 for IL-6 (P = 0 009).
IL-8 and PCT correlated with the duration of fever by lin-
ear regression (IL-8: P < 0 0001, R2 = 0 42; PCT: P < 0 0001,
R2 = 0 45). IL-6 also showed a correlation with the time of
fever, but only on Spearman’s test (P = 0 001).
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Figure 1: Kinetics of cytokines (observed means in pg/mL) on days 1, 2, 3, 5, and 14 of fever in febrile neutropenic patients. For better
visualization, IL-21 (near absent expression) and G-CSF (very high levels due to filgrastim administration) were not shown.
Table 4: Factor analysis loadings of the three factors of the solution.
Loadings > 0.7 (in bold) confirm that variables are represented by
each factor.
1 2 3
IL-8 −0.04 0.95 0.19
IL-6 −0.04 0.91 0.23
IL-21 0.99 −0.02 0.02
IL-17 0.98 −0.03 0.00
IL-12/23p40 0.96 −0.06 −0.02
IL-10 0.01 0.89 −0.24
TNF-α 0.99 0.00 0.02
GM-CSF 0.03 0.11 0.98
IL-1β 0.99 −0.02 0.02
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4. Discussion
In our septic patients, the cytokines with a greater expression
were IL-6 and IL-8, which are produced by multiple types of
cells, and were apparently spared by chemotherapy. IL-6 is
produced by lymphocytes, macrophages, dendritic cells,
endothelial cells, fibroblasts, and smooth muscle cells in
response to stimulation with LPS, IL-1, and TNF-α. IL-6
levels tend to remain high in sepsis, and one of its biological
effects is the induction of fever [15, 16]. IL-8 also is produced
by fibroblasts and epithelial, mesothelial, and endothelial
cells, in addition to monocytes and neutrophils [17]. TNF-α
and IL-1β, produced primarily by activated macrophages,
had little expression. The peaks of systemic release of TNF-α
and IL-1β occur quickly (90min after endotoxin administra-
tion in human volunteers for TNF and 180min for IL-1β)
[18]. In addition, both do not show consistent patterns of
gene expression and are highly variable between individuals,
and their expression is downregulated by IL-6 and IL-10 [16].
The inflammatory response in sepsis of febrile neutropenia
appears to be similar to that in the nonneutropenic patients
[19]. In our study, the anti-inflammatory response, charac-
terized by IL-10 expression, accompanied IL-8 and IL-6
variance in time, showing that pro- and anti-inflammatory
responses occur early and simultaneously. The shared
variance of IL-8, IL-6, and IL-10 (factor 2 in factor analysis)
was correlated with the development of sepsis. The shared
variance of IL-21, IL-17, IL-12/23p40, TNF-α, and IL-1β
(factor 1) correlated positively with neutrophil and lympho-
cyte counts and negatively with CRP, suggesting that this
variance may be related to homeostasis regarding sterile
inflammation, because CRP means decreased toward day 5,
as leukocytes recovered.
The kinetics of cytokines observed in the mixed models
showed that there was initially a “storm” of IL-6 and IL-8,
which was sustained on the first 2 days, correlating with the
time of fever and decreasing on the third day, in a proinflam-
matory response similar to what is described in nonneutro-
penic patients [20]. The concomitant anti-inflammatory
response of IL-10 also decreases sharply after the second
day. The fitting lines show that the expression of these
cytokines becomes similar between nonseptic and septic
patients at approximately day 10.
IL-12 and IL-23 share the subunit p40, and it was this
subunit that was measured in this study. Therefore, it is not
possible to determine the individual contribution of IL-12
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Figure 2: Fitting lines of IL-6, IL-8, and IL-10 (base-10 log scale) for the occurrence of sepsis (dashed line and diamonds) or not (solid line
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or IL-23. However, the linear relationship between the mea-
surements of IL-12/23p40 and IL-17 (R2 = 0 88) suggests that
we have been dealing almost exclusively with IL-23, which is
the inducer of IL-17, and that observed fluctuations must
belong to axis IL-23/Th17. IL-12 and IL-23 are secreted
mainly by resident tissue macrophages and dendritic cells.
Whereas IL-12 promotes differentiation of naïve CD4 cells
in Th1 producing interferon (IFN-γ) cells, IL-23 does not
promote Th differentiation directly due to the absence or
low expression of IL-23 receptors (IL-23R) in naïve lympho-
cytes. In mice, the transforming growth factor beta (TGF-β),
IL-1, and IL-6 induce the expression of retinoic acid-related
orphan receptor gamma (ROR-γt), a lineage-specific tran-
scription factor that induces the transcription of IL-17A
and IL-17F, encoding genes in CD4+ naïve cells [21, 22].
The later stages of Th17 differentiation (clonal expansion,
phenotypic stabilization with IL-17 production) apparently
depend on IL-23 expression [23]. Although the IL-23/Th17
axis has been described as the orchestrator of the recruitment
and activation of neutrophils and a key player in chronic
inflammation and autoimmunity, recent evidence suggests
that the effector cytokines Th17 (IL-17 and IL-22) play a cru-
cial role in maintaining mucosal immunity, protecting
against extracellular bacteria and fungi. This includes the
intestinal lining, where these cytokines assist in maintaining
the physical barrier intact and induce the expression of anti-
microbial peptides to prevent invasion by luminal bacteria
[24]. It is well known that the intestinal flora is a major
source of serious infections in patients undergoing chemo-
therapy [25]. Our nonseptic patients had higher IL-12/
23p40 and IL-17 means, suggesting integrity of the IL-23/
Th17 axis, which is not apparent in the septic patients. Five
of the eight isolates from blood cultures in our septic patients
were intestinal bacteria. The low expression of IL-17 can be
explained by depletion and impairment of naïve Th cells after
cytotoxic chemotherapy and by the reduction in absolute
numbers of lymphocytes producing IL-17 in septic patients
[26, 27]. Depletion of CD4+ cells may also explain the
almost-absent expression of IL-21, another cytokine involved
in Th17 differentiation: IL-6 induces IL-21 expression, which
in turn amplifies an autocrine loop to induce more IL-21 and
IL-23 receptors in naïve CD4+ cells. Both IL-21 and IL-23
together with TGF-β can induce IL-17 expression irrespec-
tive of IL-6 [28]. This deficiency in the IL-23/Th17 axis
may be an important immunosuppressant factor in febrile
neutropenic sepsis. It is not possible, however, to establish
causal relationships.
Various authors have studied the role of biomarkers for
diagnosing bacterial infections in children with febrile neu-
tropenia. Stryjewski et al. evaluated IL-6, IL-8, and PCT for
discrimination of bacterial sepsis in neutropenic children
and observed an excellent discriminating power of PCT 24
hours after admission. For IL-6 and IL-8, the power of dis-
crimination was considered good after 24 and 48 hours after
admission, and the best observed result was the combination
of IL-8 and PCT (sensitivity 94% and specificity 90% for PCT
>500 and IL-8 >20 pg/mL) [29]. Urbonas et al. described an
IL-10 sensitivity of 73% and a specificity of 92% (cut-off:
18 pg/mL) for discrimination of sepsis or bacteremia in
febrile neutropenic children [30]. In our study, we tried to
evaluate the usefulness of other cytokines as discriminators
of sepsis on admission, within the first 24 hours of fever,
when clinical signs of severe infections can still be subtle or
absent in neutropenic children. We confirmed the observa-
tions of other authors about the good performance of IL-6,
IL-8, IL-10, and PCT. We also demonstrated that the
Table 5: Medians of biomarkers (pg/mL) on the day 1 of fever in
patients receiving filgrastim or not. ∗Mann–Whitney and median
tests; ‡Mann–Whitney test; †determined by Monte Carlo
simulation with 10,000 tables.
Filgrastim No filgrastim P P 99% CI†
G-CSF 5838 302.9 0.000∗ 0.000-0.000
IL-8 155.4 58.2 0.011‡ 0.006–0.011
IL-6 132 39.5 0.007∗ 0.003–0.007
IL-10 5.51 1.2 0.004‡ 0.002–0.04
PCT 223.3 98.1 0.07‡ 0.06–0.08
Table 6: Performance of IL-6, IL-8, PCT, and IL-10 for
discrimination of sepsis on day 1 of fever. AUC: area under the
ROC curve.
AUC
Standard
error
P
95% CI
(sample)
95% CI
(Bootstrap)
Youden
(J)
IL-6 0.87 0.062 0.000 0.75–0.99 0.76–0.8 0.65
IL-8 0.86 0.074 0.000 0.72–1 0.83–0.87 0.7
PCT 0.89 0.054 0.000 0.78–0.99 0.87–0.90 0.64
IL-10 0.83 0.08 0.001 0.67–0.98 0.79–0.83 0.6
0.00
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Figure 4: Temporal evolution of leukocytes along the days
(in means, cells/μL).
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combination of one of these markers improves the perfor-
mance of a risk assessment model (e.g., IL-8 >240+high
risk, or PCT >180+high risk). In this sense, IL-8 has been
validated by Miedema et al., being useful when combined
with clinical parameters to stratify patients at risk for bacte-
rial infections, in order to shorten antibiotic treatment in
selected patients [31]. The other cytokines in our study
(IL-1β, TNF-α, IL-12/23p40, IL-21, IL-17, G-CSF, and
GM-CSF) do not appear to be useful markers for clinical
decisions regarding sepsis.
High local and systemic concentrations of G-CSF are
found in patients with infections. At sites of infection,
G-CSF is produced by monocytes and macrophages [32]. In
animal models of sepsis, pretreatment with G-CSF attenu-
ated serum levels of TNF induced by LPS, as well as ex vivo
TNF release in different populations of macrophages. This
did not occur with the addition of G-CSF in cultures of mac-
rophages, indicating that pretreatment alters the cytokine
response in sepsis indirectly, by indefinite factors or effector
cells [33]. In blood samples from volunteers treated with
G-CSF subcutaneously 1 day before collection, ex vivo stim-
ulation with LPS caused an increase in IL-6, IL-8, IL-10,
G-CSF, IL-1 receptor antagonist (IL-1ra), and soluble
TNF receptor release and reduced the release of IFN-γ
and GM-CSF [34]. These studies show inflammatory and
anti-inflammatory effects of G-CSF. We found no studies
about effects of filgrastim on the inflammatory response
in febrile neutropenic children. In our study, filgrastim
administration apparently upregulates the systemic release
of IL-8, IL-6, and IL-10 on the first day of fever, with little
impact on sepsis discrimination capability.
This study has several limitations, the most obvious being
the small number of patients. The number of biomarkers that
we measured was also limited, and we left out important
cytokines in the inflammatory and anti-inflammatory
response, such as IFN-γ and IL-4. Another limitation was
the commercial nonavailability of IL-23p19 for the CBA
method at the time. However, as strengths, we raised the need
to clarify in future studies the role of filgrastim in inflamma-
tory and anti-inflammatory responses in febrile neutropenic
children and also to elucidate the role of IL-23-Th17 axis in
the sepsis of these patients.
5. Conclusions
During febrile neutropenia, pro- and anti-inflammatory
cytokines are detected simultaneously in the blood in children
with oncological diseases. We observed deficiencies in the
IL-23-Th17 axis and the IL-21 expression in these patients,
which may characterize aspects of immunosuppression in
those progressing to sepsis. The study further supports
the usefulness of IL-8, IL-6, IL-10, and PCT as biomarkers
of sepsis in febrile neutropenic children. Filgrastim appears
to regulate upward expression of these markers on the first
day of fever, with little impact on diagnostic performance.
Abbreviations
CBA: Cytometric bead array
CRP: C-reactive protein
DAMP: Damage associated molecular patterns
ELISA: Enzyme-linked immunosorbent assay
G-CSF: Granulocyte colony-stimulating factor
GM-CSF: Granulocyte-macrophage colony-stimulating factor
ICU: Intensive care unit
IL: Interleukin
PAMP: Pathogen-associated molecular patterns
PCT: Procalcitonin
ROC curve: Receiver operating characteristic curve
SIRS: Systemic inflammatory response syndrome
Th: T helper cells
TNF: Tumor necrosis factor.
Table 7: Performance of cutoff values and combinations of the biomarkers IL-6, IL-8, IL-10, and PCT (all in pg/mL) as sepsis discriminators
on day 1 of fever, compared with the high-risk assessment model. S= sensitivity; E= specificity; PPV= positive predictive value;
NPV=negative predictive value; LR+= positive likelihood ratio; LR−=negative likelihood ratio.
IL-6> 170 IL-8> 240 PCT> 180 IL-10> 6 High risk
S 0.69 0.69 0.80 0.69 1.00
E 0.95 1.00 0.68 0.86 0.44
PPV 0.90 1.00 0.50 0.75 0.42
NPV 0.84 0.85 0.89 0.83 1.00
LR+ 9.00 − 1.00 3.00 0.71
LR− 0.19 0.18 0.12 0.21 0.00
Youden J 0.65 0.69 0.48 0.56 0.44
IL-8> 240 + high risk PCT> 180 + high risk IL-10> 6 + PCT> 180 IL-8> 100 + PCT> 100 IL-6> 50 + PCT> 100
S 0.69 0.77 0.69 0.85 0.85
E 1.00 0.86 0.91 0.91 0.82
PPV 1.00 0.77 0.82 0.85 0.73
NPV 0.85 0.86 0.83 0.91 0.90
LR+ — 3.33 4.50 5.50 2.75
LR− 0.18 0.16 0.20 0.10 0.11
Youden J 0.69 0.63 0.60 0.76 0.66
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